General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: An experimental study

BMJ Open

Volumn 4, Issue 5, 2014, Pages

  Jansen, Jesse ^a,b   Bonner, Carissa ^a,b   McKinn, Shannon ^a,b   Irwig, Les ^a   Glasziou, Paul ^a,c   Doust, Jenny ^a,c   Teixeira Pinto, Armando ^a   Hayen, Andrew ^d   Turner, Robin ^a   McCaffery, Kirsten ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BOND UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABSOLUTE RISK; AGE; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; COMPARATIVE STUDY; EXPERIMENTAL STUDY; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; INDIVIDUAL RISK FACTOR; PHARMACEUTICAL CARE; PRESCRIPTION; RISK; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL DECISION-MAKING; FEMALE; GENERAL PRACTICE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; RISK FACTORS; RISK MANAGEMENT;

EID: 84901025051     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-004812     Document Type: Article

References (39)

1. Ryden L, Scherer M, Syvanne M. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635 -701.
2. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;S0735-1097(13) 06028-2.
4. Boon N, Boyle R, Bradbury K, et al. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl 2):ii1-67.
5. New Zealand Guidelines Group. Cardiovascular disease risk assessment (updated 2013). Wellington: New Zealand Guidelines Group, 2013.
6. Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010;170:27-40.
7. Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 2012;344:e3318.
8. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardiovascular disease risk calculators. Circulation 2013;127:1948-56.
9. D'Agostino R, Ramachandran S, Vasan R, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
10. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. Approved by the National Health and Medical Research Council 2009.
11. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Approved by the National Health and Medical Research Council 2012.
12. Doust J, Sanders S, Shaw J, et al. The prevention of cardiovascular disease: how does assessment based on absolute risk affect who is treated versus individual risk factors? Aus Fam Physician 2012;41:805-9.
13. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41. (Pubitemid 40179232)
14. Sheridan S, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res 2008;8:60.
15. Graham I, Stewart M, Hertog M, et al. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006;13:839-45. (Pubitemid 44454860)
16. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254-9.
17. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009;191:324-9.
18. Sposito AC, Ramires JAF, Jukema JW, et al. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Curr Med Res Opin 2009;25:1171-8.
19. Bonner C, Jansen J, McKinn S, et al . General practitioners' use of different cardiovascular risk assessment strategies: a qualitative study. Med J Aust 2013;199:1-5.
20. Hobbs FDR, Jukema JW, Da Silva PM, et al. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 2010;103:727-39.
21. van Steenkiste B, van der Weijden T, Stoffers H, et al. Barriers to implementing cardiovascular risk tables in routine practice. Scand J Pri Health Care 2004;22:32-7. (Pubitemid 38477888)
22. Torley D, Zwar N, Comino E, et al. GPs' views of absolute cardiovascular risk and its role in primary prevention. Aust Fam Physician 2005;34:503-04.
23. Chen L, Rogers S, Colagiuri S, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000. Med J Aust 2008;189:319-22.
24. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010;213:598-603.
25. Peabody JW, Luck J, Glassman P, et al. Comparisons of vignettes, standardized patients, and chart abstractions. A prospective validation study of 3 measures for validating quality. JAMA 2000;283:1715-22. (Pubitemid 30196212)
26. Mohammed MA, Marshall T, Gill P. The effect of chance variability in blood pressure readings on the decision making of general practitioners: an internet-based case vignette study. PLoS ONE 2012;7:e46556.
27. Weiner M, Wells S, Kerse N. Perspectives of general practitioners towards evaluation and treatment of cardiovascular disease among older people. J Prim Health Care 2009;1:198-206.
28. Johansen ME, Gold KJ, Sen A, et al. A national survey of the treatment of hyperlipidemia in primary prevention. JAMA Intern Med 2013;173:586-8.
29. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management-2005. Heart Lung Circ 2005;14:275.
30. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010.
31. Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment. Med Decis Making 2012;32:498-506.
32. van Staa T-P, Smeeth L, Ng ESW, et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart 2013;99:1597-602.
33. Wu J, Zhu S, Yao GL, et al . Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. PLoS ONE 2013;8:e67611.
34. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
35. Reiner Ž. Polypill is not a 'vaccine-like'solution for primary cardiovascular disease prevention in all parts of the world. J Epidemiol Community Health 2013;67:981-2.
36. van der Weijden T, Pieterse AH, Koelewijn-van Loon MS, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf 2013;22:855-63.
37. Krumholz HM. Target cardiovascular risk rather than cholesterol concentration. BMJ 2013;347:f7110.
38. Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich) 2006;8(8 Suppl 2):15-20.
39. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6. (Pubitemid 30013066)